Logo
x

Search

Subscribe Now

Spinal Muscular Atrophy

PharmaShots Interview: Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy

PharmaShots Interview: Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy

  • May 10, 2022
Biogen to Initiate P-IIIb ASCEND Study Evaluating Higher Doses of Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy

Biogen to Initiate P-IIIb ASCEND Study Evaluating Higher Doses of Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrop...

  • September 16, 2021
Chugai's Evrysdi (risdiplam) Receives MHLW's Approval for the Treatment of Spinal Muscular Atrophy

Chugai's Evrysdi (risdiplam) Receives MHLW's Approval for the Treatment of Spinal Muscular Atrophy

  • June 24, 2021
Roche Reports New Interim Data of JEWELFISH & RAINBOWFISH Studies for Evrysdi (risdiplam) to Treat Spinal Muscular Atrophy

Roche Reports New Interim Data of JEWELFISH & RAINBOWFISH Studies for Evrysdi (risdiplam) to Treat Spinal Muscular Atrophy

  • June 11, 2021
Roche's Evrysdi (risdiplam) Receives Health Canada's Approval for Spinal Muscular Atrophy in Adults and Children

Roche's Evrysdi (risdiplam) Receives Health Canada's Approval for Spinal Muscular Atrophy in Adults and Children

  • April 16, 2021
Roche and PTC's Evrysdi (risdiplam) Receive the EC's Approval as First and Only at Home Treatment For Spinal Muscular Atrophy

Roche and PTC's Evrysdi (risdiplam) Receive the EC's Approval as First and Only at Home Treatment For Spinal Muscular Atrophy

  • March 30, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.